| |
| |
|
| Insider
Information: |
Koenig Sheldon L. |
| Relationship: |
President and CEO, Dir... |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
766,816 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,456,950 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
766,816 |
|
|
| Total
Value |
$1,456,950 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
5
|
|
Stock
price went up :
|
1
|
1
|
| Stock
price went down : |
1
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -14.2%
|
-158.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Portola Pharmaceuticals Inc |
PTLA |
EVP, Chief Commercial ... |
2020-07-02 |
0 |
2019-01-31 |
0 |
Premium* |
|
|
Esperion Therapeutics, Inc. |
ESPR |
President and CEO, Dir... |
2024-03-14 |
766,816 |
2021-01-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2024-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
454,000 |
766,816 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2023-05-09 |
4 |
B |
$1.26 |
$25,192 |
D/D |
20,000 |
312,816 |
2.81 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2023-03-17 |
4 |
S |
$1.78 |
$12,479 |
D/D |
(6,999) |
292,816 |
0 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2023-03-07 |
4 |
S |
$5.06 |
$27,510 |
D/D |
(5,441) |
194,815 |
0 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2022-09-19 |
4 |
S |
$6.94 |
$23,548 |
D/D |
(3,394) |
198,257 |
0 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2022-08-05 |
4 |
B |
$5.80 |
$49,950 |
D/D |
8,606 |
198,771 |
2.81 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2022-06-17 |
4 |
S |
$4.99 |
$22,719 |
D/D |
(4,552) |
190,165 |
0 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2022-03-17 |
4 |
S |
$4.58 |
$2,615 |
D/D |
(571) |
194,717 |
0 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
116,000 |
195,288 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President and CEO |
• • – |
2021-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
50,000 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Chief Operating Officer |
• – – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, Chief Commercial Officer |
• – – |
2020-07-02 |
4 |
D |
$18.00 |
$100,134 |
D/D |
(5,563) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, Chief Commercial Officer |
• – – |
2020-06-18 |
4 |
A |
$8.36 |
$4,080 |
D/D |
488 |
488 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, Chief Commercial Officer |
• – – |
2020-03-02 |
4 |
D |
$9.68 |
$41,885 |
D/D |
(4,327) |
37,991 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, Chief Commercial Officer |
• – – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
41,523 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, Chief Commercial Officer |
• – – |
2019-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
